Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV

BACKGROUND: Dolutegravir (DTG) monotherapy results in virologic failure and the development of DTG resistance. Here, we evaluated virologic outcomes of patients switched to DTG functional mono- or dual therapy with a non-cytosine nucleoside analog (NA). METHODS: This retrospective, single center stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Rolle, Charlotte-Paige, Nguyen, Vu, Hinestrosa, Federico, DeJesus, Edwin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094570/
https://www.ncbi.nlm.nih.gov/pubmed/33941212
http://dx.doi.org/10.1186/s12981-021-00352-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094570/
https://www.ncbi.nlm.nih.gov/pubmed/33941212
http://dx.doi.org/10.1186/s12981-021-00352-0

Ejemplares similares